Abstract
AbstractBackgroundLimited recent data exist on prescribing patterns and patient characteristics for glucagon-like peptide 1 receptor agonists (GLP-1 RAs), an important drug class used as anti-diabetic medication (ADM) for patients with type 2 diabetes mellitus (T2D) and/or anti-obesity medication (AOM) in patients with overweight or obesity.For brevity, we use the term GLP-1 RA to refer to both GLP-1 RA and dual GLP-1 RA/GIP medications.ObjectiveTo describe recent trends in prescribing and dispensing of GLP-1-based medications in the USMethodsUsing a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provide more than 18% of all daily clinical care in the US, we identified people who were prescribed a GLP-1-based medication between January 01, 2018 and December 31, 2023. We describe prescribing volumes and patient characteristics over time, by medication, and by FDA- labeled use. Among the subset of patients for whom post-prescription dispensing data is available, we describe the proportion and characteristics of patients who were and were not dispensed a GLP-1 RA following their prescription.Results1,063,200 patients were prescribed a GLP-1 RA between January 2018 and December 2023, with 4,213,888 total prescriptions during this period. Among first-time prescriptions for which use could be established, ADMs accounted for 86.6% and AOMs accounted for 13.4%. The most common first-time medication was semaglutide (n = 559,880). Among those with available data, 71.5% of first-time ADM prescriptions overall and 74.9% in September 2023 had a fill within 60 days. By comparison, 45.6% of first-time AOM prescriptions overall and 32.1% in September 2023 had a fill within 60 days.
Publisher
Cold Spring Harbor Laboratory
Reference13 articles.
1. Truveta. (2024). Truveta’s Approach to Patient Privacy. https://resources.truveta.com/patient-privacy
2. Centers for disease control and prevention. “National diabetes statistics report”. 2020. https://www.cdc.gov/diabetes/data/statistics-report/index.html.
3. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
4. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
5. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief, no 360;National Center for Health Statistics,2020